WikiTrademarks - Search, analyse, and monitor trademark applications.

Trademark: ALMOND THERAPY: TARGETING THE AMYGDALA

Put your brand on the blockchain and timestamp its proof of existence at wikitrademarks.io

Tweet this

Track updates on ALMOND THERAPY: TARGETING THE AMYGDALA

Mark Identification

Proof of use for ALMOND THERAPY: TARGETING THE AMYGDALA

We do not have any records of a proof of use for ALMOND THERAPY: TARGETING THE AMYGDALA at this moment.

Click here to add a proof of use for ALMOND THERAPY: TARGETING THE AMYGDALA

Possible trademark infringements of ALMOND THERAPY: TARGETING THE AMYGDALA

Basic Information about ALMOND THERAPY: TARGETING THE AMYGDALA

Serial Number
97182740
Filing Date
21 Dec 2021
Mark Drawing Code
4

Classifications

Declare the trademark use of ALMOND THERAPY: TARGETING THE AMYGDALA on the blockchain with WikiTrademarks.io.

First use of ALMOND THERAPY: TARGETING THE AMYGDALA anywhere
No first use declared yet.
First use in commerce
There is no first use of this trademark in commerce detected yet.
Status Code
6
International Code
035
US Codes
100; 101; 102
First use of ALMOND THERAPY: TARGETING THE AMYGDALA anywhere
No first use declared yet.
First use in commerce
There is no first use of this trademark in commerce detected yet.
Status Code
6
International Code
036
US Codes
100; 101; 102
First use of ALMOND THERAPY: TARGETING THE AMYGDALA anywhere
No first use declared yet.
First use in commerce
There is no first use of this trademark in commerce detected yet.
Status Code
6
International Code
041
US Codes
100; 101; 107
First use of ALMOND THERAPY: TARGETING THE AMYGDALA anywhere
No first use declared yet.
First use in commerce
There is no first use of this trademark in commerce detected yet.
Status Code
6
International Code
042
US Codes
100; 101
First use of ALMOND THERAPY: TARGETING THE AMYGDALA anywhere
No first use declared yet.
First use in commerce
There is no first use of this trademark in commerce detected yet.
Status Code
6
International Code
044
US Codes
100; 101

Who owns ALMOND THERAPY: TARGETING THE AMYGDALA?

1. PsiloTec Health Solutions Inc. Calgary, Alberta

Correspondent

Charles G. Zug NELSON MULLINS RILEY & SCARBOROUGH LLP
301 SOUTH COLLEGE STREET
SUITE 2300, IP DEPARTMENT
CHARLOTTE, NC 28202

Put your brand on the blockchain and timestamp its proof of existence at Wikitrademarks.io

Tweet this

Track updates on ALMOND THERAPY: TARGETING THE AMYGDALA